Lucinactant, a Synthetic Surfactant for the Treatment of Acute Respiratory Distress Syndrome Caused by COVID-19: Phase 1/2A Trial
{{output}}
Background: One unique feature of COVID-19-associated acute respiratory distress syndrome (ARDS) is surfactant deficiency because SARS-CoV-2 specifically attacks alveolar type 2 cells. ... ...
